Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CimetrA (Argent BioPharma)
- Development stage
- Unknown
- Lead developer
- Argent BioPharma
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
CimetrA (MGC-006) is an investigational, nano-micellar pharmaceutical formulation developed by Argent BioPharma (formerly MGC Pharmaceuticals) for the treatment of severe inflammatory conditions, particularly COVID-19. It is a multi-component synergetic composition containing curcumin, Boswellia serrata, and vitamin C (with earlier formulations also containing artemisinin), delivered via Graft Polymer's GraftBio self-nanoemulsifying drug delivery system (SNEDDS) to enhance bioavailability. CimetrA acts as an anti-inflammatory and immunomodulatory agent by suppressing IL-32 expression, increasing intracellular heme oxygenase-1 (HO-1) levels, and inhibiting the overproduction of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α, thereby preventing the onset of a cytokine storm. The drug is administered as an oral spray and has been evaluated in Phase II and Phase III clinical trials for hospitalized patients with moderate COVID-19.
- Other names
- ArtemiCArtemiC RescueCimetra
02
Targets
HMOX1 (Heme oxygenase 1)IL1B (Interleukin-1 beta)IL32 (IL-32)IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on CimetrA (Argent BioPharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CimetrA (Argent BioPharma).